Granted Patent B2

US 12,234,503 · App. 16/794,686 · Granted Feb 25, 2025

Inventors: Stephanie Rae Hennek (Medford, MA); Mael Manesse (Medford, MA); Abdul Mohammed (Cambridge, MA); Xi Chen (West Newton, MA); Michael Jules Natan (Weston, MA)

Assignee: Ultivue, Inc.

C12Q1/6816C12Q1/68C12Q1/6804C12Q1/6806C12Q1/6818C12Q1/682C12Q1/6823C12Q1/6832C12Q1/6874G01N33/543G01N33/54306G01N33/54333G01N33/58G01N33/587

Abstract

Claims (32)

1. A method to test a tissue sample for the location of at least four distinctive targets comprising:

(1) contacting a tissue sample being tested for the presence of at least four distinctive targets with at least four distinctive corresponding target-specific binding partners, wherein each target-specific binding partner of different specificity is linked to a different docking strand, and wherein each docking strand is an oligonucleotide;

(2) contacting the tissue sample with circular DNA amplifier strands having complementarity to the different docking strands;

(3) contacting the tissue sample with DNA polymerase, nucleotides, and buffer solution for rolling circle amplification, and amplifying simultaneously the different docking strands with rolling circle amplification to produce concatemers comprising repeats of the different docking strands;

(4) contacting the tissue sample with imager strands having complementarity to the different docking strands, wherein the imager strands comprise fluorescent labels, wherein step (3) occurs in the same step as step (4); and

(5) imaging the tissue sample to detect bound imager strands, thereby detecting the location of the at least four distinctive targets in the tissue sample.

2. The method of claim 1 , wherein the imager strands comprises a 3′ modification to prevent amplification of the imager strands.

3. A method to test a tissue sample for the location of at least eight distinctive targets comprising:

(1) contacting a tissue sample being tested for the presence of at least eight distinctive targets with at least eight corresponding target-specific binding partners, wherein each target-specific binding partner of different specificity is linked to a different docking strand, and wherein each docking strand is an oligonucleotide;

(2) contacting the tissue sample with circular DNA amplifier strands having complementarity to the different docking strands;

(3) contacting the tissue sample with DNA polymerase, nucleotides, and buffer solution for rolling circle amplification, and amplifying simultaneously the different docking strands with rolling circle amplification to produce concatemers comprising repeats of the different docking strands;

(4) contacting the tissue sample with imager strands having complementarity to a first subset of different docking strands corresponding to a first subset of at least four distinctive targets, wherein the imager strands comprise fluorescent labels, wherein step (3) occurs in the same step as step (4);

(5) imaging the tissue sample to detect bound imager strands of the first subset of targets;

(6) extinguishing signal from the bound imager strands;

(7) contacting the tissue sample with imager strands having complementarity to a subsequent subset of different docking strands corresponding to a subsequent subset of at least four distinctive targets different from the first subset, wherein the imager strands comprise fluorescent labels; and

(8) imaging the tissue sample to detect bound imager strands of the subsequent subset of targets, thereby detecting the location of the at least eight distinctive targets in the tissue sample.

4. The method of claim 3 , wherein the extinguishing comprises removing the bound imager strands from the docking strands.

5. The method of claim 3 , wherein the extinguishing comprises removing the fluorescent labels from the bound imager strands.

6. The method of claim 3 , wherein the extinguishing comprises inactivating the labels on the bound imager strands.

7. The method of claim 3 , wherein the extinguishing comprises enzymatically cleaving, modifying, or degrading the bound imager strands.

8. The method of claim 7 , wherein the enzyme for enzymatically cleaving is selected from glycosylase, endonuclease, DNAse, RNAse, and an enzyme that cleaves at a non-natural nucleotide.

9. The method of claim 3 , wherein the extinguishing comprises disrupting the link between the docking strand and the target-specific binding partner.

10. The method of claim 3 , wherein the extinguishing comprises a condition selected from high temperature, low ionic strength buffers, and a denaturant.

11. The method of claim 3 , wherein the extinguishing comprises a condition selected from chemical cleavage, photocleavage, and photo-bleaching.

12. The method of claim 3 , wherein the imager strand comprises at least one deoxyuridine capable of cleavage by uracil-DNA glycosylase.

13. The method of claim 3 , wherein the imager strand comprises an abasic site capable of cleavage by endonuclease.

14. The method of claim 13 , wherein the endonuclease is Endonuclease VIII.

15. The method of claim 3 , wherein the target-specific binding partner is an antibody.

16. The method of claim 3 , further comprising aligning the images from step (5) imaging.

17. The method of claim 3 , wherein at least one of the same fluorophores is used as a label on imager strands used in a first subset and a subsequent subset.

18. The method of claim 3 , further comprising repeating steps (6)-(8).

19. The method of claim 3 , wherein the imager strands comprises a 3′ modification to prevent amplification of the imager strands.

Assignments (1)

Continuity (4)

References Cited (307)